The book provides a multidisciplinary outlook on using Artificial Intelligence (AI)-based solutions in the field of Personalized Medicine and its transitioning towards Personalized Digital Medicine. The first section integrates different perspectives on AI-based solutions and highlights their potential in biomedical research and patient care. In the second section, the authors present several real-world examples that demonstrate the successful use of AI technologies in various contexts. These include examples from digital therapeutics, in silico clinical trials, and network pharmacology. In the final section of the book, the authors explore future directions in AI-enhanced biomedical technologies and discuss emerging technologies such as blockchain, quantum computing and the “metaverse”. The book includes discussions on the ethical, regulatory, and social implications for an AI-based personalized medicine. The integration of heterogeneous disciplines brings together multiple stakeholders and decision makers involved in the personalization of care. Clinicians, students, and researchers from academia and the industry can benefit from this book, since it provides foundational knowledge to drive advances in personalized biomedical research and health care. The book provides a multidisciplinary outlook on using Artificial Intelligence (AI)-based solutions in the field of Personalized Medicine and its transitioning towards Personalized Digital Medicine. The first section integrates different perspectives on AI-based solutions and highlights their potential in biomedical research and patient care. In the second section, the authors present several real-world examples that demonstrate the successful use of AI technologies in various contexts. These include examples from digital therapeutics, in silico clinical trials, and network pharmacology. In the final section of the book, the authors explore future directions in AI-enhanced biomedical technologies and discuss emerging technologies such as blockchain, quantum computing and the “metaverse”. The book includes discussions on the ethical, regulatory, and social implications for an AI-based personalized medicine. The integration of heterogeneous disciplines brings together multiple stakeholders and decision makers involved in the personalization of care. Clinicians, students, and researchers from academia and the industry can benefit from this book, since it provides foundational knowledge to drive advances in personalized biomedical research and health care. Alfredo Cesario Open Innovation Manager at the Fondazione Policlinico Universitario A. Gemelli IRCCS (Rome, Italy, www.policlinicogemelli.it). CEO, Gemelli Digital Medicine and Health Srl (GDMH, www.gdmh.it). Marika D'Oria PhD in Education and Communication. Health Communication Officer for the Scientific Directorate (Open Innovation Unit) at the Fondazione Policlinico Universitario A. Gemelli IRCCS (Rome, Italy). Charles Auffray Founding Director at the European Institute for Systems Biology and Medicine (Lyon, France) and CNRS Research Director at the Joliot Curie Transdisciplinary Laboratory and École Normale Supérieure (Lyon, France). Giovanni Scambia Scientific Director at the Fondazione Policlinico Universitario A. Gemelli IRCCS and Full Professor in “Gynecology and Obstetrics” at the Catholic University of the Sacred Heart (Rome, Italy).